A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma

Published:2023-04 Issue: Volume:Volume 10 Page:673-686
ISSN:2253-5969
Container-title:Journal of Hepatocellular Carcinoma
language:en
Short-container-title:JHC

Author:

Gan Leijuan^ORCID,Lang Mengran,Tian Xindi,Ren Shaohua^ORCID,Li Guangtao,Liu Yayue,Han Ruyu^ORCID,Zhu Kangwei,Li Huikai,Wu Qiang,Cui Yunlong,Zhang Wei,Fang Feng,Li Qiang,Song Tianqiang^ORCID

Publisher

Informa UK Limited

Subject

General Medicine

Reference49 articles.

1. Cancer statistics, 2018

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. Preoperative Systemic Chemoimmunotherapy and Sequential Resection for Unresectable Hepatocellular Carcinoma

4. A global view of hepatocellular carcinoma: trends, risk, prevention and management

5. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era;Expert Review of Molecular Diagnostics;2024-08-28

2. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis;BMC Cancer;2024-08-14

3. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review;Frontiers in Immunology;2024-05-28

4. Lenvatinib‑based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: A systematic review and meta‑analysis;Oncology Letters;2024-04-12

5. Immune Checkpoint Inhibitors, Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib or Bevacizumab in Unresectable Hepatocellular Carcinoma: A Retrospective, Multi-Center, and Propensity Score Matching Study;2024